|
1
|
Robinson BW and Lake RA: Advances in
malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Campbell NP and Kindler HL: Update on
malignant pleural mesothelioma. Semin Respir Crit Care Med.
32:102–110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peto J, Decarli A, La Vecchia C, Levi F
and Negri E: The European mesothelioma epidemic. Br J Cancer.
79:666–672. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Murayama T: Epidemic of asbestos related
diseases. Proceedings of the global Asbestos Congress (Tokyo); pp.
172004
|
|
5
|
Stewart DJ, Martin-Ucar A, Pilling JE,
Edwards JG, O'Byrne KJ and Waller DA: The effect of extent of local
resection on patterns of disease progression in malignant pleural
mesothelioma. Ann Thorac Surg. 78:245–252. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takahashi K: Emerging health effects of
asbestos in Asia. Proceedings of the Global Asbestos Congress
(Tokyo); pp. 22004
|
|
7
|
Murayama T, Takahashi K, Natori Y and
Kurumatani N: Estimation of future mortality from pleural malignant
mesothelioma in Japan based on an age-cohort model. Am J Ind Med.
49:1–7. 2006. View Article : Google Scholar
|
|
8
|
Rascoe PA, Jupiter D, Cao X, Littlejohn JE
and Smythe WR: Molecular pathogenesis of malignant mesothelioma.
Expert Rev Mol Med. 14:e122012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murakami H, Mizuno T, Taniguchi T, Fujii
M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, et
al: LATS2 is a tumor suppressor gene of malignant mesothelioma.
Cancer Res. 71:873–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujii M, Toyoda T, Nakanishi H, Yatabe Y,
Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, et al:
TGF-β synergizes with defects in the Hippo pathway to stimulate
human malignant mesothelioma growth. J Exp Med. 209:479–494. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi Y, Moura U, Opitz I, Soltermann A,
Rehrauer H, Thies S, Weder W, Stahel RA and Felley-Bosco E: Role of
hedgehog signaling in malignant pleural mesothelioma. Clin Cancer
Res. 18:4646–4656. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Testa JR, Cheung M, Pei J, Below JE, Tan
Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, et al: Germline
BAP1 mutations predispose to malignant mesothelioma. Nat Genet.
43:1022–1025. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo G, Chmielecki J, Goparaju C, Heguy A,
Dolgalev I, Carbone M, Seepo S, Meyerson M and Pass HI: Whole-exome
sequencing reveals frequent genetic alterations in BAP1, NF2,
CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res.
75:264–269. 2015. View Article : Google Scholar
|
|
14
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, et al: Phase III study of pemetrexed in combination
with cisplatin versus cisplatin alone in patients with malignant
pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsao AS, Wistuba I, Roth JA and Kindler
HL: Malignant pleural mesothelioma. J Clin Oncol. 27:2081–2090.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stahel RA and Weder W: Improving the
outcome in malignant pleural mesothelioma: Nonaggressive or
aggressive approach? Curr Opin Oncol. 21:124–130. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kindler HL, Karrison TG, Gandara DR, Lu C,
Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR,
et al: Multicenter, double-blind, placebo-controlled, randomized
phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo
in patients with malignant mesothelioma. J Clin Oncol.
30:2509–2515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brar SS, Kennedy TP, Sturrock AB,
Huecksteadt TP, Quinn MT, Whorton AR and Hoidal JR: An NAD(P)H
oxidase regulates growth and transcription in melanoma cells. Am J
Physiol Cell Physiol. 282:C1212–C1224. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lambeth JD: NOX enzymes and the biology of
reactive oxygen. Nat Rev Immunol. 4:181–189. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dworakowski R, Anilkumar N, Zhang M and
Shah AM: Redox signalling involving NADPH oxidase-derived reactive
oxygen species. Biochem Soc Trans. 34:960–964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen K, Craige SE and Keaney JF Jr:
Downstream targets and intracellular compartmentalization in Nox
signaling. Antioxid Redox Signal. 11:2467–2480. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Storz P: Reactive oxygen species in tumor
progression. Front Biosci. 10:1881–1896. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Szatrowski TP and Nathan CF: Production of
large amounts of hydrogen peroxide by human tumor cells. Cancer
Res. 51:794–798. 1991.PubMed/NCBI
|
|
24
|
Mochizuki T, Furuta S, Mitsushita J, Shang
WH, Ito M, Yokoo Y, Yamaura M, Ishizone S, Nakayama J, Konagai A,
et al: Inhibition of NADPH oxidase 4 activates apoptosis via the
AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic
cancer PANC-1 cells. Oncogene. 25:3699–3707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vaquero EC, Edderkaoui M, Pandol SJ,
Gukovsky I and Gukovskaya AS: Reactive oxygen species produced by
NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J
Biol Chem. 279:34643–34654. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng G, Cao Z, Xu X, van Meir EG and
Lambeth JD: Homologs of gp91phox: Cloning and tissue expression of
Nox3, Nox4, and Nox5. Gene. 269:131–140. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Donkó A, Péterfi Z, Sum A, Leto T and
Geiszt M: Dual oxidases. Philos Trans R Soc Lond B Biol Sci.
360:2301–2308. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Geiszt M, Witta J, Baffi J, Lekstrom K and
Leto TL: Dual oxidases represent novel hydrogen peroxide sources
supporting mucosal surface host defense. FASEB J. 17:1502–1504.
2003.PubMed/NCBI
|
|
29
|
Juhasz A, Ge Y, Markel S, Chiu A,
Matsumoto L, van Balgooy J, Roy K and Doroshow JH: Expression of
NADPH oxidase homologues and accessory genes in human cancer cell
lines, tumours and adjacent normal tissues. Free Radic Res.
43:523–532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu Y, Antony S, Juhasz A, Lu J, Ge Y,
Jiang G, Roy K and Doroshow JH: Up-regulation and sustained
activation of Stat1 are essential for interferon-gamma
(IFN-gamma)-induced dual oxidase 2 (Duox2) and dual oxidase A2
(DuoxA2) expression in human pancreatic cancer cell lines. J Biol
Chem. 286:12245–12256. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Doroshow JH, Juhasz A, Ge Y, Holbeck S, Lu
J, Antony S, Wu Y, Jiang G and Roy K: Antiproliferative mechanisms
of action of the flavin dehydrogenase inhibitors diphenylene
iodonium and di-2-thienyliodonium based on molecular profiling of
the NCI-60 human tumor cell panel. Biochem Pharmacol. 83:1195–1207.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miura Y, Thoburn CJ, Bright EC, Phelps ML,
Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, et
al: Association of Foxp3 regulatory gene expression with
graft-versus-host disease. Blood. 104:2187–2193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee YJ, Cho HN, Soh JW, Jhon GJ, Cho CK,
Chung HY, Bae S, Lee SJ and Lee YS: Oxidative stress-induced
apoptosis is mediated by ERK1/2 phosphorylation. Exp Cell Res.
291:251–266. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carbone M and Yang H: Molecular pathways:
Targeting mechanisms of asbestos and erionite carcinogenesis in
mesothelioma. Clin Cancer Res. 18:598–604. 2012. View Article : Google Scholar :
|
|
35
|
Carbone M, Ly BH, Dodson RF, Pagano I,
Morris PT, Dogan UA, Gazdar AF, Pass HI and Yang H: Malignant
mesothelioma: Facts, myths, and hypotheses. J Cell Physiol.
227:44–58. 2012. View Article : Google Scholar
|
|
36
|
Ushio-Fukai M and Nakamura Y: Reactive
oxygen species and angiogenesis: NADPH oxidase as target for cancer
therapy. Cancer Lett. 266:37–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shono T, Yokoyama N, Uesaka T, Kuroda J,
Takeya R, Yamasaki T, Amano T, Mizoguchi M, Suzuki SO, Niiro H, et
al: Enhanced expression of NADPH oxidase Nox4 in human gliomas and
its roles in cell proliferation and survival. Int J Cancer.
123:787–792. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yamaura M, Mitsushita J, Furuta S, Kiniwa
Y, Ashida A, Goto Y, Shang WH, Kubodera M, Kato M, Takata M, et al:
NADPH oxidase 4 contributes to transformation phenotype of melanoma
cells by regulating G2-M cell cycle progression. Cancer Res.
69:2647–2654. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Graham KA, Kulawiec M, Owens KM, Li X,
Desouki MM, Chandra D and Singh KK: NADPH oxidase 4 is an
oncoprotein localized to mitochondria. Cancer Biol Ther.
10:223–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Suzuki Y, Murakami H, Kawaguchi K,
Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K,
Horio Y, et al: Activation of the PI3K-AKT pathway in human
malignant mesothelioma cells. Mol Med Rep. 2:181–188.
2009.PubMed/NCBI
|
|
41
|
Cole GW Jr, Alleva AM, Zuo JT, Sehgal SS,
Yeow WS, Schrump DS and Nguyen DM: Suppression of pro-metastasis
phenotypes expression in malignant pleural mesothelioma by the PI3K
inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res.
26A:809–821. 2006.
|
